Gynecologic cancer intergroup (GCIG) consensus review for ovarian sex cord stromal tumors

Isabelle Ray-Coquard, Jubilee Brown, Philipp Harter, Diane M. Provencher, Peter C. Fong, Johanna Maenpaa, Jonathan A. Ledermann, Gunter Emons, Dominique Berton Rigaud, Rosalind M. Glasspool, Delia Mezzanzanica, Nicoletta Colombo

Research output: Contribution to journalReview article

33 Citations (Scopus)

Abstract

Sex cord stromal tumors (SCST) are rare cancers of the ovarian area in adults. They constitute a heterogeneous group of tumors that develop from the sex cords and the ovarian stroma. These tumors are detected typically at an early stage, and they may recur as late as 30 years after the initial treatment. Because 70% of the patients present with stage I tumors, surgery represents the most important therapeutic arm. There are no data to support any kind of postoperative adjuvant treatment for patients with stage IA or IB SCSTs, given the indolent nature of these neoplasms and the overall good prognosis. The long natural history of the disease may lead to repeated surgical procedure should a relapse occurs. Platinum-based chemotherapy is currently used for patients with advanced stage SCSTs or recurrent disease, with an overall response rate of 63% to 80%. The indolent nature of SCSTs with the tendency for late recurrence requires long-term follow-up.

Original languageEnglish
Pages (from-to)S42-S47
JournalInternational Journal of Gynecological Cancer
Volume24
Issue number9
DOIs
Publication statusPublished - Nov 1 2014

Fingerprint

Sex Cord-Gonadal Stromal Tumors
Neoplasms
Recurrence
Platinum
Ovarian Neoplasms
Therapeutics
Drug Therapy

Keywords

  • First-line treatment
  • Metastatic disease
  • Molecular analysis
  • Rare tumor
  • Sex cord stromal tumors

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynaecology

Cite this

Gynecologic cancer intergroup (GCIG) consensus review for ovarian sex cord stromal tumors. / Ray-Coquard, Isabelle; Brown, Jubilee; Harter, Philipp; Provencher, Diane M.; Fong, Peter C.; Maenpaa, Johanna; Ledermann, Jonathan A.; Emons, Gunter; Rigaud, Dominique Berton; Glasspool, Rosalind M.; Mezzanzanica, Delia; Colombo, Nicoletta.

In: International Journal of Gynecological Cancer, Vol. 24, No. 9, 01.11.2014, p. S42-S47.

Research output: Contribution to journalReview article

Ray-Coquard, I, Brown, J, Harter, P, Provencher, DM, Fong, PC, Maenpaa, J, Ledermann, JA, Emons, G, Rigaud, DB, Glasspool, RM, Mezzanzanica, D & Colombo, N 2014, 'Gynecologic cancer intergroup (GCIG) consensus review for ovarian sex cord stromal tumors', International Journal of Gynecological Cancer, vol. 24, no. 9, pp. S42-S47. https://doi.org/10.1097/IGC.0000000000000249
Ray-Coquard, Isabelle ; Brown, Jubilee ; Harter, Philipp ; Provencher, Diane M. ; Fong, Peter C. ; Maenpaa, Johanna ; Ledermann, Jonathan A. ; Emons, Gunter ; Rigaud, Dominique Berton ; Glasspool, Rosalind M. ; Mezzanzanica, Delia ; Colombo, Nicoletta. / Gynecologic cancer intergroup (GCIG) consensus review for ovarian sex cord stromal tumors. In: International Journal of Gynecological Cancer. 2014 ; Vol. 24, No. 9. pp. S42-S47.
@article{3cffcf62adae48c58c6ee4d69aa9d9f7,
title = "Gynecologic cancer intergroup (GCIG) consensus review for ovarian sex cord stromal tumors",
abstract = "Sex cord stromal tumors (SCST) are rare cancers of the ovarian area in adults. They constitute a heterogeneous group of tumors that develop from the sex cords and the ovarian stroma. These tumors are detected typically at an early stage, and they may recur as late as 30 years after the initial treatment. Because 70{\%} of the patients present with stage I tumors, surgery represents the most important therapeutic arm. There are no data to support any kind of postoperative adjuvant treatment for patients with stage IA or IB SCSTs, given the indolent nature of these neoplasms and the overall good prognosis. The long natural history of the disease may lead to repeated surgical procedure should a relapse occurs. Platinum-based chemotherapy is currently used for patients with advanced stage SCSTs or recurrent disease, with an overall response rate of 63{\%} to 80{\%}. The indolent nature of SCSTs with the tendency for late recurrence requires long-term follow-up.",
keywords = "First-line treatment, Metastatic disease, Molecular analysis, Rare tumor, Sex cord stromal tumors",
author = "Isabelle Ray-Coquard and Jubilee Brown and Philipp Harter and Provencher, {Diane M.} and Fong, {Peter C.} and Johanna Maenpaa and Ledermann, {Jonathan A.} and Gunter Emons and Rigaud, {Dominique Berton} and Glasspool, {Rosalind M.} and Delia Mezzanzanica and Nicoletta Colombo",
year = "2014",
month = "11",
day = "1",
doi = "10.1097/IGC.0000000000000249",
language = "English",
volume = "24",
pages = "S42--S47",
journal = "International Journal of Gynecological Cancer",
issn = "1048-891X",
publisher = "Lippincott Williams and Wilkins",
number = "9",

}

TY - JOUR

T1 - Gynecologic cancer intergroup (GCIG) consensus review for ovarian sex cord stromal tumors

AU - Ray-Coquard, Isabelle

AU - Brown, Jubilee

AU - Harter, Philipp

AU - Provencher, Diane M.

AU - Fong, Peter C.

AU - Maenpaa, Johanna

AU - Ledermann, Jonathan A.

AU - Emons, Gunter

AU - Rigaud, Dominique Berton

AU - Glasspool, Rosalind M.

AU - Mezzanzanica, Delia

AU - Colombo, Nicoletta

PY - 2014/11/1

Y1 - 2014/11/1

N2 - Sex cord stromal tumors (SCST) are rare cancers of the ovarian area in adults. They constitute a heterogeneous group of tumors that develop from the sex cords and the ovarian stroma. These tumors are detected typically at an early stage, and they may recur as late as 30 years after the initial treatment. Because 70% of the patients present with stage I tumors, surgery represents the most important therapeutic arm. There are no data to support any kind of postoperative adjuvant treatment for patients with stage IA or IB SCSTs, given the indolent nature of these neoplasms and the overall good prognosis. The long natural history of the disease may lead to repeated surgical procedure should a relapse occurs. Platinum-based chemotherapy is currently used for patients with advanced stage SCSTs or recurrent disease, with an overall response rate of 63% to 80%. The indolent nature of SCSTs with the tendency for late recurrence requires long-term follow-up.

AB - Sex cord stromal tumors (SCST) are rare cancers of the ovarian area in adults. They constitute a heterogeneous group of tumors that develop from the sex cords and the ovarian stroma. These tumors are detected typically at an early stage, and they may recur as late as 30 years after the initial treatment. Because 70% of the patients present with stage I tumors, surgery represents the most important therapeutic arm. There are no data to support any kind of postoperative adjuvant treatment for patients with stage IA or IB SCSTs, given the indolent nature of these neoplasms and the overall good prognosis. The long natural history of the disease may lead to repeated surgical procedure should a relapse occurs. Platinum-based chemotherapy is currently used for patients with advanced stage SCSTs or recurrent disease, with an overall response rate of 63% to 80%. The indolent nature of SCSTs with the tendency for late recurrence requires long-term follow-up.

KW - First-line treatment

KW - Metastatic disease

KW - Molecular analysis

KW - Rare tumor

KW - Sex cord stromal tumors

UR - http://www.scopus.com/inward/record.url?scp=84988719181&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84988719181&partnerID=8YFLogxK

U2 - 10.1097/IGC.0000000000000249

DO - 10.1097/IGC.0000000000000249

M3 - Review article

C2 - 25341579

AN - SCOPUS:84988719181

VL - 24

SP - S42-S47

JO - International Journal of Gynecological Cancer

JF - International Journal of Gynecological Cancer

SN - 1048-891X

IS - 9

ER -